Dabigatran etexilate Information for Patients / Caregivers of paediatric patients

Dabigatran etexilate-Prescriber Guide (deep vein thrombosis & pulmonary embolism)

Dabigatran etexilate-Prescriber Guide (paediatric use)

Dabigatran etexilate-Prescriber Guide (prevention of venous thromboembolic events)

Patient alert card

Dabigatran Krka Prescriber Guide for paediatrics

Dabigatran Krka Prescriber Guide for;

• Stroke prevention in atrial fibrillation

• Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (DVT/PE)

Dabigatran Krka Prescriber Guide for primary prevention of venous thromboembolic events (VTE) following elective total hip or knee replacement surgery

Patient Alert Card

Prescriber guide for paediatric use

Prescriber Guide for prevention of VTE

Prescriber Guide for stroke prevention

This guide provides recommendations for the use of dabigatran etexilate in the paediatric population in order to minimise the risk of bleeding

This guide provides recommendations for the use of dabigatran in order to minimise the risk of bleeding

This guide provides recommendations for the use of dabigatran in order to minimise the risk of bleeding

Dabigatran etexilate Information for Patients / Caregivers of paediatric patients

Information about the potential risk of bleeding during treatment with dabigatran etexilate and guidance on how to manage that risk.

• Indication
• Contraindications
• Dosing Special patient populations potentially at high risk of bleeding
• Perioperative management
• Coagulation tests and their interpretation
• Overdose
• Management of bleeding complications
• Patient Alert Card and counselling

• Indications
• Contraindications
• Perioperative management
• Dosing
• Special patient populations potentially at higher risk of bleeding
• Coagulation tests and their interpretation
• Overdose
• Management of bleeding complications
• Patient Alert Card and counselling

• Indication
• Contraindications
• Dosing
• Special patient populations potentially at high risk of bleeding
• Coagulation tests and their interpretation
• Overdose
• Management of bleeding complications
• Dabigatran etexilate Patient Alert Card and counselling

Patient Alert card

Dabigatran etexilate-Prescriber Guide (deep vein thrombosis & pulmonary embolism)

Dabigatran etexilate-Prescriber Guide (paediatric use)

Dabigatran etexilate-Prescriber Guide (prevention of venous thromboembolic events)

Inform health care professionals of the interference of Darzalex (daratumumab) with antibody screening and crossmatching

Card for patient's receiving Darzalex (daratumumab)- patient should carry this card while receiving treatment and for 6 months after treatment has ended.

Information for Blood Banks on the intereference with Antiglobulin Test _blood typing

Important Information for Healthcare Professionals

Important information for patients

Physician’s reference checklist for Deferasirox

Communication plan for deferasirox tablets

Important Information for Healthcare Professionals to Remember About Deferasirox SUN (deferasirox) Treatment

Important information for patients about your treatment and possible side effects - Deferasirox

Physician’s reference checklist for Deferasiroxdosing and biological monitoring

Important Safety Reminders for Patients taking Deferiprone tablets

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for use with girls and women of childbearing potential taking this product. It is to be completed with their specialist at least once a year to make sure they know and have understood all the risks related to the use of valproate during pregnancy and the need to avoid becoming pregnant while taking valproate.

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Educational material for Healthcare Professionals on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for male patients aged under 55 years to complete with their specialists when starting valproate

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

FOR DISPENSARY USE ONLY Dispensary A4 Poster for Pharmacy on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

This guide is an educational material as part of the additional risk minimisation program

for Duodopa. This guide is intended to inform gastroenterologists, neurologists and other

healthcare professionals (HCPs) with recommended measures to minimise gastrointestinal,

gastrointestinal device, and gastrointestinal procedure related events.

This guide is for patients and caregivers of patients who are using Duodopa as a

treatment for advanced Parkinson’s disease (PD).

Pharmacy Essential Guide for Dymista Control